bioMerieux (OTCMKTS:BMXMF) Shares Gap Up - Should You Buy?

bioMerieux (OTCMKTS:BMXMF - Get Free Report)'s share price gapped up before the market opened on Friday . The stock had previously closed at $109.61, but opened at $115.00. bioMerieux shares last traded at $115.00, with a volume of 1,012 shares trading hands.Wall Street Analysts Forecast GrowthSeparately, BNP Paribas Exane downgraded bioMerieux to a "neutral" rating in a report on Wednesday, January 28th. Two investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat, bioMerieux has an average rating of "Hold".Check Out Our Latest Report on BMXMFbioMerieux Trading Up 4.9%The stock's 50-day moving average price is $120.59 and its 200-day moving average price is $128.15. The company has a current ratio of 2.27, a quick ratio of 1.30 and a debt-to-equity ratio of 0.08. About bioMerieux (Get Free Report)bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company's product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.Read MoreFive stocks we like better than bioMerieuxThe gold chart Wall Street is terrified of…America’s 1776 happening againThis makes me furiousBuy this Gold Stock Before May 2026What a Former CIA Agent Knows About the Coming CollapseThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in bioMerieux Right Now?Before you consider bioMerieux, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and bioMerieux wasn't on the list.While bioMerieux currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here